Aptose Biosciences, Inc. (APTO) Given Average Recommendation of “Buy” by Brokerages
Shares of Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.50.
A number of research analysts recently commented on the company. HC Wainwright raised Aptose Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $1.00 to $4.00 in a research note on Thursday, September 7th. ValuEngine cut Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Monday, August 14th.
Shares of Aptose Biosciences (APTO) opened at 1.44 on Thursday. The company’s market cap is $34.60 million. The stock has a 50 day moving average of $1.49 and a 200 day moving average of $1.28. Aptose Biosciences has a 12-month low of $0.78 and a 12-month high of $2.60.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.